Join today and have your say! It’s FREE!

Stock Quote Today & Recent News Pasithea Therapeutics Equity Warrant Exp 11th Aug 2026 KTTAW

Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small... see more
0 seconds of 6 minutes, 40 secondsVolume 0%
Press shift question mark to access a list of keyboard shortcuts
00:00
06:40
06:40
 

Current News (NDAQ:KTTAW)

Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4

GlobeNewswire 6 days ago

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

GlobeNewswire November 20, 2024

Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

GlobeNewswire September 26, 2024

Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

GlobeNewswire September 26, 2024

Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies

GlobeNewswire September 9, 2024

Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board

GlobeNewswire September 3, 2024

Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire August 28, 2024

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for PAS-004 in Ongoing Phase 1 Clinical Trial

GlobeNewswire June 13, 2024

Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting

GlobeNewswire May 28, 2024

Opinion & Analysis (NDAQ:KTTAW)

No current opinion is available.

Bullboard Posts (NDAQ:KTTAW)